切换至 "中华医学电子期刊资源库"

中华移植杂志(电子版) ›› 2018, Vol. 12 ›› Issue (04) : 157 -160. doi: 10.3877/cma.j.issn.1674-3903.2018.04.003

所属专题: 经典病例 文献

论著

心脏死亡器官捐献供肾ABO血型不相容肾移植八例临床分析
李盈1, 眭维国1,(), 晏强1, 林华1, 赖柳生1, 郭骏军1, 许飞龙1, 刘平1, 陈怀周1, 谢申平1, 王磊1, 王曙1   
  1. 1. 541002 桂林,中国人民解放军联勤保障部队第九二四医院肾脏科 全军器官移植与透析治疗中心 广西代谢性疾病研究重点实验室 桂林市肾脏病研究重点实验室
  • 收稿日期:2018-08-13 出版日期:2018-11-25
  • 通信作者: 眭维国
  • 基金资助:
    广西自然科学基金(2017GXNSFAA198185); 桂林市科学研究与技术开发计划项目(201701171)

ABO blood group incompatible donation after cardiac death donor kidney transplantation: a report of 8 cases

Ying Li1, Weiguo Sui1,(), Qiang Yan1, Hua Lin1, Liusheng Lai1, Junjun Guo1, Feilong Xu1, Ping Liu1, Huaizhou Chen1, Shenping Xie1, Lei Wang1, Shu Wang1   

  1. 1. Department of Nephrology, Center of Organ Transplantation and Dialysis of People′s Liberation Army of China, Key Laboratory of Metabolic Disease of Guangxi, Guilin No. 924 Hospital of People′s Liberation Army of China, Key Laboratory of Kidney Disease of Guilin, Guilin 541002, China
  • Received:2018-08-13 Published:2018-11-25
  • Corresponding author: Weiguo Sui
  • About author:
    Corresponding author: Sui Weiguo, Email:
引用本文:

李盈, 眭维国, 晏强, 林华, 赖柳生, 郭骏军, 许飞龙, 刘平, 陈怀周, 谢申平, 王磊, 王曙. 心脏死亡器官捐献供肾ABO血型不相容肾移植八例临床分析[J]. 中华移植杂志(电子版), 2018, 12(04): 157-160.

Ying Li, Weiguo Sui, Qiang Yan, Hua Lin, Liusheng Lai, Junjun Guo, Feilong Xu, Ping Liu, Huaizhou Chen, Shenping Xie, Lei Wang, Shu Wang. ABO blood group incompatible donation after cardiac death donor kidney transplantation: a report of 8 cases[J]. Chinese Journal of Transplantation(Electronic Edition), 2018, 12(04): 157-160.

目的

探讨心脏死亡器官捐献(DCD)供肾ABO血型不相合肾移植临床疗效和安全性。

方法

回顾性分析中国人民解放军联勤保障部队第九二四医院移植科2016年12月至2018年6月实施的8例DCD供肾ABO血型不相容肾移植受者临床资料,其中男性6例,女性2例,年龄26~54岁,群体反应性抗体(PRA)阳性4例,二次肾移植2例,供受者Rh(D)血型均为阴性。根据受者初始血型抗体效价及术前PRA抗体水平制定个体化预处理方案。术后常规监测受者免疫抑制剂血药浓度,重点监测尿量、肾功能、凝血状态和血型抗体水平,PRA阳性受者注意监测供者特异性抗体水平。

结果

8例受者经个体化预处理后肾移植手术当天血型抗体IgG效价水平均≤1∶16。术后2周内7例受者血型抗体无反弹。截至2018年6月,8例受者平均随访时间6~18个月。病例1于术后第2周发生体液性排斥反应,采用蛋白A免疫吸附及大剂量丙种球蛋白冲击治疗后恢复。病例2术后2 h出现膀胱出血,持续膀胱冲洗保守治疗后止血,移植肾功能恢复正常。病例3术后第5个月并发严重肺部真菌感染,抗真菌治疗失败后并发呼吸衰竭死亡。病例6术后出现移植肾功能延迟恢复,予血液透析处理后恢复。病例7术后尿量少,术后第4天出现右下肢深静脉血栓(移植肾侧),行下腔静脉滤网植入及溶栓抗凝治疗,效果欠佳,移植肾失功后恢复血液透析治疗。病例8术后第2个月并发药物性糖尿病,目前血糖控制较好。其余2例受者移植肾功能恢复良好。

结论

根据受者初始血型抗体效价及PRA水平进行个体化预处理,可安全、有效地实施DCD供肾ABO血型不相容肾移植。

Objective

To investigate the clinical efficacy and safety of ABO incompatible donation after cardiac death (DCD) donor kidney transplantation.

Methods

Retrospective analysis of clinical data of 8 patients with ABO incompatible DCD donor kidney transplantation performed from December 2016 to June 2018 in the department of transplantation of Guilin NO.924 Hospital of People′ Liberation Army of China. Among them, 6 were male and 2 were female, aged 26-54, 4 were positive for panel reactive antibodies (PRA) and 2 were for secondary renal transplantation. The Rh (D) blood type of donors and recipients were all negative. The individualized preconditioning protocol was established according to the initial blood group antibody titer and the preoperative PRA antibody level. Postoperative routine monitoring of blood concentration of immunosuppressive agents, urine volume, renal function, coagulation status and blood group antibody level, and the change of donor specific antibody level were observed in PRA positive recipients.

Results

Blood group antibody titers were all ≤1∶16 on the day of renal transplantation in 8 recipients after individualized preconditioning. There was no rebound of blood group antibody in 7 patients within 2 weeks after transplantation. Eight recipients had been followed up for an average of 6 to 18 months up to June 2018. Case 1 developed humoral rejection at the second week after transplantation and recovered after immunosorbent assay with protein A and high dose immunoglobulin shock therapy. Case 2 developed bladder bleeding 2 h after transplantation, hemostasis was got after continuous bladder washing and the function of transplant kidney returned to normal. Case 3 was complicated with severe pulmonary fungal infection at the 5th month after transplantation and died of respiratory failure after failure of antifungal treatment. Case 6 was complicated with delayed graft function and recovered after hemodialysis. Case 7 showed less urine volume, right lower extremity deep vein thrombosis (graft side), inferior vena cava mesh implantation and thrombolytic anticoagulant therapy were ineffective and hemodialysis treatment was recovered. Case 8 complicated with drug-induced diabetes 2 months after operation. The renal graft function of the remaining recipients maintained well.

Conclusions

ABO incompatible DCD donor kidney transplantation was safe and effective with individualized preconditioning according to the initial blood group antibody titer and PRA level of the recipient.

表1 8例心脏DCD供肾ABO血型不相容肾移植供受者一般资料
表2 8例DCD供肾ABO血型不相容肾移植受者预处理方案
表3 8例DCD供肾ABO血型不相容受者围手术期血型抗体效价及PRA水平
1
Cabral JF, Braga I, Fraga A, et al. From open to laparoscopic living-donor nephrectomy: changing the paradigm in a high-volume transplant center[J]. Transplant Proc, 2015, 47(4): 903-905.
2
Fuchinoue S, Ishii Y, Sawada T, et al. The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction[J]. Transplantation, 2011, 91(8): 853-857.
3
Williams WW, Cherikh WS, Young CJ, et al. First report on the OPTN national variance: allocation of A2/A2B deceased donor kidneys to blood group B increases minority transplantation[J]. Am J Transplant, 2015, 15(12): 3134-3142.
4
Zsehiedrich S, Kramer-Zueker A, Janigen B, et al. An update on ABO-incompatible kidney transplantation[J]. Transpl Int, 2015, 28(4): 387-397.
5
Aikawa A, Kawamura T, Shishido S, et al. ABO-incompatible living-donor pediatric kidney transplantation in Japan[J].Clinics(Sao Paulo), 2014, 69(Suppl 1):S22-S27.
6
Muramatsu M, Gonzalez HD, Cacciola R, et al. ABO-incompatible renal transplants:good or bad?[J]. World J Transplant, 2014, 4(1): 18-29.
7
王显丁,邱阳,宋涂润,等. ABO血型不相容亲属活体肾移植的个体化预处理[J]. 中华器官移植杂志,2015, 36(8): 449-452.
8
Takahashi K, Saito K. ABO-incompatible kidney transplantation[J]. Transplant Rev(Orlando), 2013, 27(1): 1-8.
[1] 陈絮, 詹玉茹, 王纯华. 孕妇ABO血型联合甲状腺功能检测对预测妊娠期糖尿病的临床价值[J]. 中华妇幼临床医学杂志(电子版), 2023, 19(05): 604-610.
[2] 彭文翰. 肾移植受者早期霉酚酸强化剂量长期有效性和安全性的研究[J]. 中华移植杂志(电子版), 2023, 17(05): 0-.
[3] 中华医学会器官移植学分会, 中国医师协会器官移植医师分会, 上海医药行业协会. 中国肝、肾移植受者霉酚酸类药物应用专家共识(2023版)[J]. 中华移植杂志(电子版), 2023, 17(05): 257-272.
[4] 彭雨诗, 苗芸, 严紫嫣. 宏基因组高通量测序诊断肾移植术后华支睾吸虫感染一例[J]. 中华移植杂志(电子版), 2023, 17(05): 297-299.
[5] 戚若晨, 马帅军, 韩士超, 王国辉, 刘克普, 张小燕, 杨晓剑, 秦卫军. 肾移植术后新型冠状病毒感染单中心诊疗经验[J]. 中华移植杂志(电子版), 2023, 17(04): 232-239.
[6] 胡皓翀, 刘一霆, 郭嘉瑜, 邹寄林, 陈忠宝, 周江桥, 邱涛. 肾移植术后耐碳青霉烯类肺炎克雷伯菌感染的诊疗分析[J]. 中华移植杂志(电子版), 2023, 17(04): 246-249.
[7] 朱伟芳, 陈琳, 乔建军. 激光联合光动力疗法治疗肾移植后鲍恩样丘疹病一例[J]. 中华移植杂志(电子版), 2023, 17(04): 250-252.
[8] 吴建永. 单中心2 000例心脏死亡器官捐献肾移植发展与创新[J]. 中华移植杂志(电子版), 2023, 17(04): 0-.
[9] 刘路浩, 苏泳鑫, 曾丽娟, 张鹏, 陈荣鑫, 徐璐, 李光辉, 方佳丽, 马俊杰, 陈正. 新型冠状病毒感染疫情期间肾移植受者免疫抑制剂服药依从性研究[J]. 中华移植杂志(电子版), 2023, 17(03): 140-145.
[10] 张亚龙, 邱涛, 刘一霆, 王天宇, 孔晨阳, 喻博, 周江桥. 术前透析方式及时长对肾移植预后的影响[J]. 中华移植杂志(电子版), 2023, 17(02): 98-103.
[11] 李娜, 王丹. 肾移植受者HCV感染研究进展[J]. 中华移植杂志(电子版), 2023, 17(01): 58-62.
[12] 朱晨晨, 韩飞, 寿张飞. HCV阳性供肾移植单中心回顾性研究[J]. 中华移植杂志(电子版), 2023, 17(01): 47-53.
[13] 张修源, 吕军好, 陈大进. 2022年肾移植领域研究进展[J]. 中华移植杂志(电子版), 2023, 17(01): 32-35.
[14] 中国医师协会器官移植医师分会, 中华医学会器官移植学分会, 中华医学会外科学分会移植学组, 中国医院协会器官获取与分配工作委员会. 中国心脏死亡捐献器官评估与应用专家共识(2022版)[J]. 中华移植杂志(电子版), 2022, 16(06): 321-328.
[15] 邱成, 戴帅, 张乐希, 刘洪涛. 初始血型抗体效价水平对ABO血型不相合活体肾移植受体肾功能及免疫功能的影响[J]. 中华临床医师杂志(电子版), 2022, 16(10): 1005-1011.
阅读次数
全文


摘要